Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Abbott (ABT) to $122 from $146 and keeps an Overweight rating on the shares. The firm notes the company reported a Q4 sales miss and in-line EPS on transitory headwinds. 2026 organic sales growth guidance of 6.5%-7.5% is below prior consensus due to Nutrition headwinds persisting into the first half of 2026. EPS guide was in line, Wells adds.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Buy Rating on Abbott: Near‑Term Nutrition Headwinds Offset by High-Growth MedTech and Attractive 2026 Valuation
- Abbott Laboratories Earnings Call: Devices Offset Nutrition Drag
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Midday Fly By: GE Aerospace reports Q4 beat, P&G reports mixed Q2
- Abbott falls -8.8%